Posted by Michael Wonder on 24 Oct 2021
Patient and payer incentives to use patented brand name drugs vs authorised generic drugs in Medicare Part D
18 October 2021 - This cross-sectional study of Medicare formulary and pricing data for quarter 3 of 2020 found that most Part D plans offered brand-name drug–only or both brand-name and authorised generic drug coverage.
Although Medicare beneficiaries who filled insulin and direct-acting antiviral prescriptions would spend less out of pocket with authorised generic drug use, plans and Medicare would likely spend more on these authorised generic drugs than brand-name drugs for beneficiaries with total drug spending below Medicare’s catastrophic threshold.
